• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

    2/25/25 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JAZZ alert in real time by email

    – Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 –

    – Xywav® and Epidiolex® revenues grew 16% and 15% year-over-year, respectively, in 2024 –

    – Oncology revenues grew 9% year-over-year in 2024, surpassed $1.1 billion –

    – Ziihera® approved in 2L HER2+ (IHC3+) BTC; first sales achieved in December 2024 –

    – 2025 guidance reflects continued top- and bottom-line growth –

    DUBLIN, Feb. 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the full year and fourth quarter of 2024 and provided guidance for 2025.

    "2024 was another strong year as our proven team delivered significant top- and bottom-line growth along with record total revenues of over $4 billion. Our diversified portfolio spanning sleep1, epilepsy and oncology, with each annualizing at over $1 billion, continued to drive growth," said Bruce Cozadd, chairman and chief executive officer, Jazz Pharmaceuticals. "We are pleased with the continued progress of our late-stage pipeline assets, including the recent launch of Ziihera in 2L HER2+ (IHC3+) BTC, upcoming top-line data readout from the HERIZON-GEA-01 trial in 1L GEA, which we now expect in the second half of 2025, and highly encouraging results from the Phase 3 IMforte trial, which we expect to submit as part of an sNDA for Zepzelca® in 1L ES-SCLC in the first half of 2025."

    Mr. Cozadd continued, "The strength of our 2024 results reinforces our confidence that Jazz is well-positioned to deliver top- and bottom-line growth in 2025 and drive long-term shareholder value. Our focus remains on disciplined capital allocation, which we expect to drive growth of our diversified commercial portfolio, continue advancement of our pipeline and provide flexibility to remain active in corporate development."

    Key Highlights

    • Total revenues in 2024 grew 6% year-over-year; generated over $1.4 billion in cash from operations.
    • Zanidatamab:
      • Received U.S. FDA approval of and launched Ziihera in 2L HER2+ (IHC3+) BTC.
      • Top-line PFS data from zanidatamab in Phase 3 1L GEA expected in 2H25.
    • On track to submit an sNDA in 1H25 for Zepzelca in combination with Tecentriq® (atezolizumab) as maintenance therapy in 1L ES-SCLC based on the potentially practice-changing results from the Phase 3 IMforte trial.
    • Top- and bottom-line growth expected in 2025; 2025 total revenue guidance of $4.15 - $4.40 billion, representing 5% growth at the midpoint.
      • Total revenue guidance is underpinned by expected continued growth in diversified commercial portfolio spanning sleep1, epilepsy and oncology.

    ________________________________

    1 Total sleep revenue includes: Xywav, branded Xyrem and high-sodium oxybate authorized generic royalty revenues.

    Business Updates

    Commercial Updates

    Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution:

    • Xywav net product sales increased 16% to $1,473.2 million in 2024 and increased 19% to $401.0 million in 4Q24 compared to the same periods in 2023.
    • Meaningful Xywav net patient adds in 4Q24 (approximately 525 patients) with approximately 14,150 active Xywav patients exiting 4Q24, comprised of:
      • Approximately 10,250 narcolepsy patients.
      • Approximately 3,900 idiopathic hypersomnia (IH) patients, with 350 net patient adds.
    • Xywav is the only low-sodium oxybate, the #1 branded treatment for narcolepsy2 and the only FDA-approved therapy to treat IH.

    Xyrem® (sodium oxybate) oral solution and high-sodium oxybate authorized generic (AG) royalties:

    • Xyrem net product sales decreased 59% to $233.8 million in 2024 and decreased 54% to $49.3 million in 4Q24 compared to the same periods in 2023.
    • Royalties from high-sodium oxybate AGs increased by $141.7 million to $217.6 million in 2024 and increased $15.9 million to $55.3 million in 4Q24, compared to the same periods in 2023.

    Epidiolex/Epidyolex® (cannabidiol):

    • Epidiolex/Epidyolex net product sales increased 15% to $972.4 million in 2024 and increased 14% to $275.0 million in 4Q24 compared to the same periods in 2023.
    • Outside of the U.S., Epidyolex is approved in more than 35 countries.
    • Presented data at the American Epilepsy Society 2024 Annual meeting, including novel findings from the BECOME-LTC, BECOME-TSC and EpiCom studies, demonstrating the meaningful impact of Epidiolex in the treatment of patients with rare epilepsies including benefits of Epidiolex's benefits beyond seizure control.
    • Remain confident in achieving blockbuster status for Epidiolex/Epidyolex in 2025.

    Rylaze®/Enrylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn):

    • Rylaze/Enrylaze net product sales increased 4% to $410.8 million in 2024 and were in line in 4Q24 compared to the same periods in 2023 despite headwinds from Children's Oncology Group (COG) protocol changes that impacted timing of asparaginase administration.
    • The temporary impact to Rylaze net product sales due to previously announced COG pediatric acute lymphoblastic leukemia (ALL) protocol updates is still expected to normalize by early 2025.

    Zepzelca (lurbinectedin): 

    • Zepzelca net product sales increased 11% to $320.3 million in 2024 and increased 6% to $78.3 million in 4Q24 compared to the same periods in 2023.
    • Based on potentially practice-changing positive results from the Phase 3 IMforte trial, the Company plans to submit a supplemental New Drug Application (sNDA) for Zepzelca's use in combination with Tecentriq as maintenance therapy in first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC) in 1H25.

    Ziihera (zanidatamab-hrii): 

    • Ziihera net product sales were $1.1 million in 2024 and 4Q24 after the initial product launch and availability in December of 2024 following FDA approval in November.
    • Initial positive reception by prescribers with the first patient treated in December.
    • Ziihera added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology.
    • Ziihera added to European Society for Medical Oncology® (ESMO®) Clinical Practice Guidelines for Biliary Tract Cancers.

    __________________________

    2 Based on 4Q24 Xywav net product sales.

    Key Pipeline Highlights

    Zanidatamab:

    • In 4Q24, announced U.S. FDA granted accelerated approval of Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC).
    • The pivotal HERIZON-GEA-01 trial, evaluating zanidatamab in 1L gastroesophageal adenocarcinoma (GEA), is expected to read out in 2H25 based on an updated assessment of progression events. Recruitment for the trial remains on track.
    • Data presented at the San Antonio Breast Cancer Symposium 2024 continued to underscore zanidatamab's potential for patients previously treated with trastuzumab deruxtecan (T-DXd) and showcased the advancement of our clinical program in breast cancer.
    • The Phase 3 EmpowHER-BC-303 trial to evaluate zanidatamab plus chemotherapy or trastuzumab plus chemotherapy in patients with HER2-positive breast cancer whose disease has progressed on previous T-DXd treatment continues to enroll patients.
    • First patient enrolled in the Phase 2 pan-tumor trial to evaluate HER2-positive solid tumors.

    Financial Highlights



    Three Months Ended

    December 31,



    Year Ended

    December 31,

    (In thousands, except per share amounts)

    2024



    2023



    2024



    2023

    Total revenues

    $    1,088,173



    $   1,011,935



    $   4,068,950



    $   3,834,204

    GAAP net income

    $       191,115



    $        94,154



    $      560,120



    $      414,832

    Non-GAAP adjusted net income

    $       405,863



    $      345,286



    $   1,369,729



    $   1,295,824

    GAAP earnings per share

    $             3.11



    $            1.42



    $            8.65



    $            6.10

    Non-GAAP adjusted EPS

    $             6.60



    $            5.02



    $          20.90



    $          18.29

    GAAP net income for 2024 was $560.1 million, or $8.65 per diluted share, compared to $414.8 million, or $6.10 per diluted share, for 2023. GAAP net income for 4Q24 was $191.1 million, or $3.11 per diluted share, compared to a GAAP net income of $94.2 million, or $1.42 per diluted share, for 4Q23. 

    Non-GAAP adjusted net income for 2024 was $1,369.7 million, or $20.90 per diluted share, compared to $1,295.8 million, or $18.29 per diluted share, for 2023. Non-GAAP adjusted net income for 4Q24 was $405.9 million, or $6.60 per diluted share, compared to $345.3 million, or $5.02 per diluted share, for 4Q23. 

    Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release.

    Total Revenues



    Three Months Ended

    December 31,



    Year Ended

    December 31,

    (In thousands)

    2024



    2023



    2024



    2023

    Xywav

    $      400,964



    $      337,019



    $   1,473,202



    $   1,272,977

    Xyrem

    49,290



    106,721



    233,816



    569,730

    Epidiolex/Epidyolex

    275,047



    240,622



    972,423



    845,468

    Sativex

    5,173



    5,137



    18,877



    19,668

    Total Neuroscience

    730,474



    689,499



    2,698,318



    2,707,843

    Rylaze/Enrylaze

    101,487



    101,747



    410,846



    394,226

    Zepzelca

    78,328



    74,010



    320,318



    289,533

    Defitelio/defibrotide

    57,650



    51,083



    216,565



    184,000

    Vyxeos

    53,247



    46,912



    162,595



    147,495

    Ziihera

    1,051



    —



    1,051



    —

    Total Oncology

    291,763



    273,752



    1,111,375



    1,015,254

    Other

    2,974



    4,088



    11,471



    13,846

    Product sales, net

    1,025,211



    967,339



    3,821,164



    3,736,943

    High-sodium oxybate AG royalty revenue

    55,307



    39,387



    217,575



    75,918

    Other royalty and contract revenues

    7,655



    5,209



    30,211



    21,343

    Total revenues

    $   1,088,173



    $   1,011,935



    $   4,068,950



    $   3,834,204

    Total revenues increased 6% in 2024 and 8% in 4Q24 compared to the same periods in 2023.

    Total neuroscience revenue, including high-sodium oxybate AG royalty revenue, was $2,915.9 million in 2024, an increase of 5% compared to $2,783.8 million in 2023 and $785.8 million in 4Q24, an increase of 8% compared to $728.9 million in 4Q23. The increase in 2024 and 4Q24 was due to higher Xywav and Epidiolex/Epidyolex net product sales together with increased high-sodium oxybate AG royalty revenue, partially offset by decreased Xyrem net product sales.

    Oncology net product sales were $1,111.4 million in 2024, an increase of 9% compared to $1,015.3 million in 2023 and $291.8 million in 4Q24, an increase of 7% compared to $273.8 million in 2023, and included higher net product sales from Defitelio/defibrotide which increased 18% in 2024 and 13% in 4Q24 and Zepzelca which increased 11% in 2024 and 6% in 4Q24. In 4Q24, Rylaze net product sales were negatively impacted due to an update to the COG pediatric treatment protocols for ALL, which impacts the timing of asparaginase administration.

    Operating Expenses and Effective Tax Rate



    Three Months Ended

    December 31,



    Year Ended

    December 31,

    (In thousands, except percentages)

    2024



    2023



    2024



    2023

    GAAP:















    Cost of product sales

    $     128,713



    $     107,243



    $     445,713



    $     435,577

    Gross margin

    87.4 %



    88.9 %



    88.3 %



    88.3 %

    Selling, general and administrative

    $     369,287



    $     396,034



    $  1,385,294



    $  1,343,105

    % of total revenues

    33.9 %



    39.1 %



    34.0 %



    35.0 %

    Research and development

    $     240,500



    $     216,608



    $     884,000



    $     849,658

    % of total revenues

    22.1 %



    21.4 %



    21.7 %



    22.2 %

    Acquired in-process research and development

    $              —



    $       18,000



    $       10,000



    $       19,000

    Income tax benefit1

    $      (57,912)



    $      (33,089)



    $      (91,429)



    $    (119,912)

    Effective tax rate 1

    (43.5) %



    (53.8) %



    (19.4) %



    (40.2) %

    _________________________

    1.

    The GAAP income tax benefit increased in the three months ended December 31, 2024, compared to the same period in 2023, primarily due to patent box benefits recognized in the period and decreased in the year ended December 31, 2024, compared to the same period in 2023, primarily due to the change in income mix across our jurisdictions, partially offset by patent box benefits.

     



    Three Months Ended

    December 31,



    Year Ended

    December 31,

    (In thousands, except percentages)

    2024



    2023



    2024



    2023

    Non-GAAP adjusted:















    Cost of product sales

    $       86,492



    $       71,238



    $     295,897



    $     269,079

    Gross margin

    91.6 %



    92.6 %



    92.3 %



    92.8 %

    Selling, general and administrative

    $     323,167



    $     300,520



    $  1,226,724



    $  1,110,948

    % of total revenues

    29.7 %



    29.7 %



    30.1 %



    29.0 %

    Research and development

    $     220,857



    $     201,107



    $     809,327



    $     784,811

    % of total revenues

    20.3 %



    19.9 %



    19.9 %



    20.5 %

    Acquired in-process research and development

    $              —



    $       18,000



    $       10,000



    $       19,000

    Income tax expense1

    $            308



    $       20,475



    $     131,307



    $       93,260

    Effective tax rate1

    0.1 %



    5.6 %



    8.7 %



    6.7 %

    _________________________

    1.

    The non-GAAP income tax expense decreased in the three months ended December 31, 2024, compared to the same period in 2023, primarily due to patent box benefits recognized in the period and increased in the year ended December 31, 2024, compared to the same period in 2023, due to the change in income mix across our jurisdictions, partially offset by patent box benefits.

    Changes in operating expenses in 2024 and 4Q24 over the prior year periods are primarily due to the following:

    • Cost of product sales, on a GAAP and non-GAAP adjusted basis, increased in 2024 and 4Q24, compared to the same periods in 2023, primarily due to higher inventory provisions and changes in product mix. Cost of product sales, on a GAAP basis, included lower acquisition accounting inventory fair value step up expense in 2024 as compared to the previous period.
    • Selling, general and administrative (SG&A) expenses, on a GAAP and non-GAAP adjusted basis, increased in 2024 compared to the same period in 2023, primarily due to higher compensation-related expenses, increased investment in sales and marketing and increased litigation costs, partially offset, on a GAAP basis, by costs related to impairment of facility assets and program terminations in 2023. SG&A expenses, on a GAAP basis, decreased in 4Q24 compared to the same period in 2023, primarily due to the impairment of facility assets in 4Q23, partially offset by higher compensation related expenses. SG&A expenses, on a non-GAAP adjusted basis, increased in 4Q24 primarily due to higher compensation-related expenses.
    • Research and development (R&D) expenses, on a GAAP and non-GAAP adjusted basis, increased in 2024 and 4Q24, compared to the same period in 2023, primarily due to increased compensation related expenses and clinical study costs primarily related to zanidatamab, partially offset by reduced costs related to JZP150 and JZP385.
    • Acquired in-process research and development (IPR&D) expense in 2024, on a GAAP and non-GAAP adjusted basis, related to an upfront payment made in connection with our asset purchase and collaboration agreement with Redx Pharma plc. Acquired IPR&D expense in 2023, on a GAAP and non-GAAP adjusted basis, primarily related to an upfront payment made in connection with our licensing and collaboration agreement with Autifony Therapeutics Limited.

    Cash Flow and Balance Sheet

    As of December 31, 2024, cash, cash equivalents and investments were $3.0 billion, and the outstanding principal balance of the Company's long-term debt was $6.2 billion. In addition, the Company had undrawn borrowing capacity under a revolving credit facility of $885.0 million. For the year ended December 31, 2024, the Company generated $1.4 billion of cash from operations reflecting strong business performance and continued financial discipline. In January 2025, the Company made a voluntary prepayment of $750.0 million principal amount on the Term Loan B.

    2025 Financial Guidance

    Jazz Pharmaceutical's full year 2025 financial guidance is as follows:

    (In millions)

    Guidance

    Total Revenues



    $4,150 - $4,400



    (In millions, except per share amounts and percentages)

    GAAP



    Non-GAAP

    Gross margin %

    88 %



    92%1,6

    SG&A expenses

    $1,404 - $1,483



    $1,250 - $1,3102,6

    R&D expenses

    $792 - $851



    $720 - $7703,6

    Effective tax rate

    (5)% - 10%



    13% - 15%4,6

    Net income

    $560 - $720



    $1,400 - $1,5005,6

    Net income per diluted share

    $9.15 - $11.50



    $22.50 - $24.005,6

    Weighted-average ordinary shares used in per share calculations

    62 - 63



    62 - 63

    ___________________________

    1.

    Excludes $135-$155 million of amortization of acquisition-related inventory fair value step-up and $14-$16 million of share-based compensation expense.

    2.

    Excludes $154-$173 million of share-based compensation expense.

    3.

    Excludes $72-$81 million of share-based compensation expense.

    4.

    Excludes 18%-5% from the GAAP effective tax rate of (5)%-10% relating to the income tax effect of adjustments between GAAP net income and non-GAAP adjusted net income, resulting in a non-GAAP adjusted effective tax rate of 13%-15%.

    5.

    Beginning with the 2025 financial guidance presented in this press release, the company will no longer include an adjustment for non-cash interest expense in its non-GAAP adjusted financial measures. Accordingly, any historical non-GAAP adjusted financial measures presented by the company in the future, beginning with the company's earnings press release for the first quarter of 2025, will not include an adjustment for non-cash interest expense. Any comparative historical periods presented will also be updated to reflect this change beginning with the company's earnings press release for the first quarter of 2025. However, for purposes of comparability with the company's prior presentations of non-GAAP financial measures, the historical non-GAAP financial measures presented in this press release include an adjustment for non-cash interest expense.

    6.

    See "Non-GAAP Financial Measures" below. Reconciliations of non-GAAP adjusted guidance measures are included above and in the table titled "Reconciliation of GAAP to non-GAAP Adjusted 2025 Net Income Guidance" at the end of this press release.

    Conference Call Details

    Jazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. ET (9:30 p.m. GMT) to provide a business and financial update and discuss its 2024 full year and 4Q24 results and 2025 guidance.

    Audio webcast/conference call: 

    U.S. Dial-In Number: +1 800 715 9871

    Ireland Dial-In Number: +353 1800 943 926

    Additional global dial-in numbers are available here.

    Passcode: 5080203

    Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

    A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.

    About Jazz Pharmaceuticals

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

    Non-GAAP Financial Measures

    To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this press release and the accompanying tables. In particular, the Company presents non-GAAP adjusted net income (and the related per share measure) and its line-item components, as well as certain non-GAAP adjusted financial measures derived therefrom, including non-GAAP adjusted gross margin percentage and non-GAAP adjusted effective tax rate. Non-GAAP adjusted net income (and the related per share measure) and its line-item components exclude from GAAP reported net income (and the related per share measure) and its line-item components certain items, as detailed in the reconciliation tables that follow, and in the case of non-GAAP adjusted net income (and the related per share measure), adjust for the income tax effect of the non-GAAP adjustments. In this regard, the components of non-GAAP adjusted net income, including non-GAAP adjusted cost of product sales, SG&A expenses and R&D expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP adjusted net income measure.

    The Company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts and that each of these non-GAAP financial measures, when considered together with the Company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the Company's results from period to period, to its forward-looking guidance, and to identify operating trends in the Company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the Company's financial performance. Jazz Pharmaceuticals' management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the Company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for Jazz Pharmaceuticals' management, the Company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the Company uses in assessing its own operating performance and making operating decisions. These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles in the reconciliation tables that follow. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; and the Company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. In this regard, the company has determined that, beginning with the 2025 financial guidance presented in this press release, it will no longer include an adjustment for non-cash interest expense in its non-GAAP adjusted financial measures. Accordingly, any historical non-GAAP adjusted financial measures presented by the company in the future, beginning with the company's earnings press release for the first quarter of 2025, will not include an adjustment for non-cash interest expense. Any comparative historical periods presented will also be updated to reflect this change beginning with the company's earnings press release for the first quarter of 2025. However, for purposes of comparability with the company's prior presentations of non-GAAP financial measures, the historical non-GAAP financial measures presented in this press release include an adjustment for non-cash interest expense. Likewise, the Company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by Jazz Pharmaceuticals in this press release and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

    Caution Concerning Forward-Looking Statements

    This press release contains forward-looking statements, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, including the Company's 2025 financial guidance and the Company's expectations related thereto and anticipated catalysts; expectations that Xywav will remain the #1 branded treatment for narcolepsy and Epidiolex achieving blockbuster status in 2025; the ability to generate growth and long-term shareholder value; the Company's advancement of pipeline programs and the timing of development activities, regulatory activities and submissions related thereto, including plans to submit a sNDA for Zepzelca in 1L ES-SCLC in the first half of 2025; planned or anticipated clinical trial events, including with respect to initiations, enrollment and data read-outs, and the anticipated timing thereof, including: top-line PFS data from a Phase 3 trial of zanidatamab in 1L GEA; and the Company's development, regulatory and commercialization strategy; the Company's expectations with respect to its products and product candidates and the potential of the Company's products and product candidates and the potential regulatory path related thereto, including Zepzelca's potential to change current practice in 1L ES-SCLC; the Company's capital allocation and corporate development strategy; the potential successful future development, manufacturing, regulatory and commercialization activities; the Company's ability to realize the commercial potential of its products; the Company's net product sales and goals for net product sales from new and acquired products; the Company's views and expectations relating to its patent portfolio, including with respect to expected patent protection, as well as expectations with respect to exclusivity; the Company's clinical trials confirming clinical benefit or enabling regulatory submissions; planned or anticipated regulatory submissions and filings, and the anticipated timing thereof; potential regulatory approvals; and other statements that are not historical facts. These forward-looking statements are based on the Company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties.

    Actual results and the timing of events could differ materially from those anticipated in such forward- looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of, and revenue from, Xywav, Rylaze and Epidiolex/Epidyolex and other marketed products; the introduction of new products into the U.S. market that compete with, or otherwise disrupt the market for the Company's products and product candidates; effectively launching and commercializing the Company's other products and product candidates; the successful completion of development and regulatory activities with respect to the Company's product candidates, obtaining and maintaining adequate coverage and reimbursement for the Company's products; the time-consuming and uncertain regulatory approval process, including the risk that the Company's current and/or planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all; the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the Company's business operations and financial results; geopolitical events, including international tariffs and the conflict between Russia and Ukraine and related sanctions; macroeconomic conditions, including global financial markets, rising interest rates and inflation and recent and potential banking disruptions; regulatory initiatives and changes in tax laws; market volatility; protecting and enhancing the Company's intellectual property rights and the Company's commercial success being dependent upon the Company obtaining, maintaining and defending intellectual property protection and exclusivity for its products and product candidates; delays or problems in the supply or manufacture of the Company's products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements, including those governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these transactions and successfully integrating acquired product candidates, products and businesses; the Company's ability to realize the anticipated benefits of its corporate development transactions and its collaborations and license agreements with third parties; the sufficiency of the Company's cash flows and capital resources; the Company's ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; the Company's ability to meet its projected long-term goals and objectives, in the time periods that the Company anticipates, or at all, and the inherent uncertainty and significant judgments and assumptions underlying the Company's long-term goals and objectives; fluctuations in the market price and trading volume of the Company's ordinary shares; the timing and availability of alternative investment opportunities; and other risks and uncertainties affecting the Company, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and future filings and reports by the Company. Other risks and uncertainties of which the Company is not currently aware may also affect the Company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.

     

    JAZZ PHARMACEUTICALS PLC

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME

    (In thousands, except per share amounts)

    (Unaudited)





    Three Months Ended

    December 31,



    Year Ended

    December 31,



    2024



    2023



    2024



    2023

    Revenues:















    Product sales, net

    $    1,025,211



    $       967,339



    $    3,821,164



    $    3,736,943

    Royalties and contract revenues

    62,962



    44,596



    247,786



    97,261

    Total revenues

    1,088,173



    1,011,935



    4,068,950



    3,834,204

    Operating expenses:















    Cost of product sales (excluding amortization of

    acquired developed technologies)

    128,713



    107,243



    445,713



    435,577

    Selling, general and administrative

    369,287



    396,034



    1,385,294



    1,343,105

    Research and development

    240,500



    216,608



    884,000



    849,658

    Intangible asset amortization

    158,903



    151,553



    627,313



    608,284

    Acquired in-process research and development

    —



    18,000



    10,000



    19,000

    Total operating expenses

    897,403



    889,438



    3,352,320



    3,255,624

    Income from operations

    190,770



    122,497



    716,630



    578,580

    Interest expense, net

    (51,256)



    (70,324)



    (238,097)



    (289,438)

    Foreign exchange gain (loss)

    (6,295)



    9,353



    (8,182)



    8,787

    Income before income tax benefit and equity in loss of

    investees

    133,219



    61,526



    470,351



    297,929

    Income tax benefit

    (57,912)



    (33,089)



    (91,429)



    (119,912)

    Equity in loss of investees

    16



    461



    1,660



    3,009

    Net income

    $       191,115



    $         94,154



    $       560,120



    $       414,832

















    Net income per ordinary share:















    Basic

    $            3.16



    $             1.50



    $             9.06



    $             6.55

    Diluted

    $             3.11



    $             1.42



    $             8.65



    $             6.10

    Weighted-average ordinary shares used in per share

    calculations - basic

    60,538



    62,578



    61,838



    63,291

    Weighted-average ordinary shares used in per share

    calculations - diluted

    61,503



    69,673



    66,007



    72,066

     

    JAZZ PHARMACEUTICALS PLC

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In thousands)

    (Unaudited)





    December 31,

    2024



    December 31,

    2023

    ASSETS







    Current assets:







    Cash and cash equivalents

    $     2,412,864



    $     1,506,310

    Investments

    580,000



    120,000

    Accounts receivable, net of allowances

    716,765



    705,794

    Inventories

    480,445



    597,039

    Prepaid expenses

    177,411



    185,476

    Other current assets

    261,543



    320,809

    Total current assets

    4,629,028



    3,435,428

    Property, plant and equipment, net

    173,413



    169,646

    Operating lease assets

    53,582



    65,340

    Intangible assets, net

    4,755,695



    5,418,039

    Goodwill

    1,716,323



    1,753,130

    Deferred tax assets, net

    560,245



    477,834

    Deferred financing costs

    9,489



    6,478

    Other non-current assets

    114,482



    67,464

    Total assets

    $    12,012,257



    $   11,393,359

    LIABILITIES AND SHAREHOLDERS' EQUITY







    Current liabilities:







    Accounts payable

    $          77,869



    $        102,750

    Accrued liabilities

    910,947



    793,914

    Current portion of long-term debt

    31,000



    604,954

    Income taxes payable

    18,757



    35,074

    Total current liabilities

    1,038,573



    1,536,692

    Long-term debt, less current portion

    6,077,640



    5,107,988

    Operating lease liabilities, less current portion

    38,938



    59,225

    Deferred tax liabilities, net

    676,736



    847,706

    Other non-current liabilities

    86,614



    104,751

    Total shareholders' equity

    4,093,756



    3,736,997

    Total liabilities and shareholders' equity

    $    12,012,257



    $   11,393,359

     

    JAZZ PHARMACEUTICALS PLC

    SUMMARY OF CASH FLOWS 

    (In thousands)

    (Unaudited)





    Year Ended

    December 31,



    2024



    2023

    Net cash provided by operating activities

    $     1,395,908



    $     1,092,007

    Net cash used in investing activities

    (508,195)



    (163,062)

    Net cash provided by (used in) financing activities

    20,516



    (305,254)

    Effect of exchange rates on cash and cash equivalents

    (1,675)



    1,137

    Net increase in cash and cash equivalents

    $        906,554



    $        624,828

     

    JAZZ PHARMACEUTICALS PLC

    RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

    (In thousands, except per share amounts)

    (Unaudited)





    Three Months Ended

    December 31,



    Year Ended

    December 31,



    2024



    2023



    2024



    2023



    Net

    Income



    Diluted

    EPS1



    Net

    Income



    Diluted

    EPS1



    Net

    Income



    Diluted

    EPS1



    Net

    Income



    Diluted

    EPS1

    GAAP reported

    $  191,115



    $        3.11



    $    94,154



    $        1.42



    $    560,120



    $      8.65



    $   414,832



    $      6.10

    Intangible asset amortization

    158,903



    2.58



    151,553



    2.18



    627,313



    9.50



    608,284



    8.44

    Share-based compensation

    expense

    70,190



    1.14



    52,941



    0.76



    248,045



    3.76



    226,841



    3.15

    Acquisition accounting

    inventory fair value step-up

    37,794



    0.61



    32,352



    0.46



    135,014



    2.05



    151,446



    2.10

    Other costs2

    —



    —



    61,727



    0.89



    —



    —



    85,215



    1.18

    Non-cash interest expense3

    6,081



    0.10



    6,123



    0.09



    21,973



    0.33



    22,378



    0.31

    Income tax effect of above

    adjustments

    (58,220)



    (0.94)



    (53,564)



    (0.77)



    (222,736)



    (3.37)



    (213,172)



    (2.95)

    Effect of assumed conversion

    of the 2024 Notes and the

    2026 Notes1

    —



    —



    —



    (0.01)



    —



    (0.02)



    —



    (0.04)

    Non-GAAP adjusted

    $  405,863



    $        6.60



    $  345,286



    $        5.02



    $ 1,369,729



    $   20.90



    $  1,295,824



    $   18.29

    Weighted-average ordinary

    shares used in diluted per

    share calculations - GAAP and

    non-GAAP1

    61,503







    69,673







    66,007







    72,066





    ________________________________________________

    Explanation of Adjustments and Certain Line Items:

    1.

    Diluted EPS was calculated using the "if-converted" method in relation to the 1.50% exchangeable senior notes due 2024, or the 2024 Notes and the 2.000% exchangeable senior notes due 2026, or the 2026 Notes. In August 2023 and July 2024, we made irrevocable elections to net share settle the 2024 Notes and the 2026 Notes, respectively. As a result, the assumed issuance of ordinary shares upon exchange of the 2024 Notes and the 2026 Notes have only been included in the calculation of diluted net income per ordinary share, on a GAAP and on a non-GAAP adjusted basis, in each period up to the date each irrevocable election was made. Net income per diluted share, on a GAAP and on a non-GAAP adjusted basis, for the year ended December 31, 2024, included 3.5 million shares related to the assumed conversion of the 2026 Notes and the associated interest expense, net of tax, add-back to GAAP reported net income and non-GAAP adjusted net income of $10.8 million and $9.7 million, respectively. Net income per diluted share, on a GAAP and on a non-GAAP adjusted basis, for the three months and the year ended December 31, 2023 included 6.4 million shares and 8.0 million shares, respectively, related to the assumed conversion of the 2024 Notes and the 2026 Notes and the associated interest expense, net of tax, add-back to GAAP reported net income of $4.9 million and $24.9 million, respectively, and the associated interest expense, net of tax, add-back to non-GAAP adjusted net income of $4.4 million and $22.2 million, respectively.

    2.

    Includes costs related to the impairment of facility assets and program terminations.

    3.

    Non-cash interest expense associated with debt issuance costs.

     

    JAZZ PHARMACEUTICALS PLC

    RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

    CERTAIN LINE ITEMS - FOR THE THREE MONTHS ENDED DECEMBER 31, 2024 AND 2023

    (In thousands, except percentages)

    (Unaudited)





    Three months ended December 31, 2024



    Cost of

    product

    sales



    Gross

    margin



    Selling,

    general and

    administrative



    Research

    and

    development



    Intangible

    asset

    amortization



    Interest

    expense, net



    Income tax

    expense

    (benefit)



    Effective

    tax rate

    GAAP Reported

    $ 128,713



    87.4 %



    $     369,287



    $  240,500



    $ 158,903



    $    51,256



    $  (57,912)



    (43.5) %

    Non-GAAP Adjustments:































    Intangible asset amortization

    —



    —



    —



    —



    (158,903)



    —



    —



    —

    Share-based compensation

    expense

    (4,427)



    0.5



    (46,120)



    (19,643)



    —



    —



    —



    —

    Acquisition accounting

    inventory fair value step-up

    (37,794)



    3.7



    —



    —



    —



    —



    —



    —

    Non-cash interest expense

    —



    —



    —



    —



    —



    (6,081)



    —



    —

    Income tax effect of above

    adjustments

    —



    —



    —



    —



    —



    —



    58,220



    43.6

    Total of non-GAAP adjustments     

    (42,221)



    4.2



    (46,120)



    (19,643)



    (158,903)



    (6,081)



    58,220



    43.6

    Non-GAAP Adjusted

    $   86,492



    91.6 %



    $     323,167



    $  220,857



    $           —



    $    45,175



    $         308



    0.1 %

     



    Three months ended December 31, 2023



    Cost of

    product

    sales



    Gross

    margin



    Selling,

    general and

    administrative



    Research

    and

    development



    Intangible

    asset

    amortization



    Acquired

    IPR&D



    Interest

    expense,

    net



    Income tax

    expense

    (benefit)



    Effective

    tax rate

    GAAP Reported

    $  107,243



    88.9 %



    $    396,034



    $  216,608



    $ 151,553



    $  18,000



    $ 70,324



    $ (33,089)



    (53.8) %

    Non-GAAP Adjustments:



































    Intangible asset amortization

    —



    —



    —



    —



    (151,553)



    —



    —



    —



    —

    Share-based compensation

    expense

    (3,653)



    0.4



    (33,787)



    (15,501)



    —



    —



    —



    —



    —

    Restructuring and other

    costs

    —



    —



    (61,727)



    —



    —



    —



    —



    —



    —

    Non-cash interest expense

    —



    —



    —



    —



    —



    —



    (6,123)



    —



    —

    Acquisition accounting

    inventory fair value step-up

    (32,352)



    3.3



    —



    —



    —



    —



    —



    —



    —

    Income tax effect of above

    adjustments

    —



    —



    —



    —



    —



    —



    —



    53,564



    59.4

    Total of non-GAAP

    adjustments

    (36,005)



    3.7



    (95,514)



    (15,501)



    (151,553)



    —



    (6,123)



    53,564



    59.4

    Non-GAAP Adjusted

    $ 71,238



    92.6 %



    $    300,520



    $  201,107



    $           —



    $  18,000



    $ 64,201



    $  20,475



    5.6 %

     

    JAZZ PHARMACEUTICALS PLC

    RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

    CERTAIN LINE ITEMS - FOR THE YEAR ENDED DECEMBER 31, 2024 AND 2023

    (In thousands, except percentages)

    (Unaudited)





    Year ended December 31, 2024



    Cost of

    product

    sales



    Gross

    margin



    Selling,

    general and

    administrative



    Research

    and

    development



    Intangible

    asset

    amortization



    Acquired

    IPR&D



    Interest

    expense,

    net



    Income tax

    expense

    (benefit)



    Effective

    tax rate

    GAAP Reported

    $ 445,713



    88.3 %



    $ 1,385,294



    $  884,000



    $ 627,313



    $  10,000



    $  238,097



    $  (91,429)



    (19.4) %

    Non-GAAP Adjustments:



































    Intangible asset amortization

    —



    —



    —



    —



    (627,313)



    —



    —



    —



    —

    Share-based compensation expense 

    (14,802)



    0.5



    (158,570)



    (74,673)



    —



    —



    —



    —



    —

    Non-cash interest expense

    —



    —



    —



    —



    —



    —



    (21,973)



    —



    —

    Acquisition accounting inventory fair

    value step-up

    (135,014)



    3.5



    —



    —



    —



    —



    —



    —



    —

    Income tax effect of above

    adjustments

    —



    —



    —



    —



    —



    —



    —



    222,736



    28.1

    Total of non-GAAP adjustments

    (149,816)



    4.0



    (158,570)



    (74,673)



    (627,313)



    —



    (21,973)



    222,736



    28.1

    Non-GAAP Adjusted

    $ 295,897



    92.3 %



    $ 1,226,724



    $  809,327



    $           —



    $  10,000



    $  216,124



    $ 131,307



    8.7 %

     



    Year ended December 31, 2023



    Cost of

    product

    sales



    Gross

    margin



    Selling,

    general and

    administrative



    Research

    and

    development



    Intangible

    asset

    amortization



    Acquired

    IPR&D



    Interest

    expense,

    net



    Income tax

    expense

    (benefit)



    Effective

    tax rate

    GAAP Reported

    $ 435,577



    88.3 %



    $  1,343,105



    $   849,658



    $   608,284



    $ 19,000



    $  289,438



    $ (119,912)



    (40.2) %

    Non-GAAP Adjustments:



































    Intangible asset amortization

    —



    —



    —



    —



    (608,284)



    —



    —



    —



    —

    Share-based compensation expense

    (15,052)



    0.4



    (146,942)



    (64,847)



    —



    —



    —



    —



    —

    Other costs

    —



    —



    (85,215)



    —



    —



    —



    —



    —



    —

    Non-cash interest expense

    —



    —



    —



    —



    —



    —



    (22,378)



    —



    —

    Acquisition accounting inventory fair

    value step-up

    (151,446)



    4.1



    —



    —



    —



    —



    —



    —



    —

    Income tax effect of above adjustments

    —



    —



    —



    —



    —



    —



    —



    213,172



    46.9

    Total of non-GAAP adjustments

    (166,498)



    4.5



    (232,157)



    (64,847)



    (608,284)



    —



    (22,378)



    213,172



    46.9

    Non-GAAP Adjusted

    $ 269,079



    92.8 %



    $  1,110,948



    $   784,811



    $            —



    $ 19,000



    $  267,060



    $    93,260



    6.7 %

     

    JAZZ PHARMACEUTICALS PLC

    RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED 2025 NET INCOME AND DILUTED EPS GUIDANCE

    (In millions, except per share amounts)

    (Unaudited)





    Net Income



    Diluted EPS

    GAAP guidance

    $560 - $720



    $9.15 - $11.50

    Intangible asset amortization

    610 - 660



    9.70 - 10.60

    Acquisition accounting inventory fair value step-up

    135 - 155



    2.15 - 2.50

    Share-based compensation expense

    240 - 270



    3.80 - 4.35

    Income tax effect of above adjustments

    (215) - (235)



    (3.40) - (3.75)

    Non-GAAP guidance

    $1,400 - $1,500



    $22.50 - $24.00









    Weighted-average ordinary shares used in per share calculations - GAAP and

    non-GAAP

    62 - 63

    Contacts:

    Investors:

    Jeff Macdonald

    Executive Director, Investor Relations

    Jazz Pharmaceuticals plc

    [email protected]

    Ireland +353 1 634 3211

    U.S. +1 650 496 2717

    Media:

    Kristin Bhavnani

    Head of Global Corporate Communications

    Jazz Pharmaceuticals plc

    [email protected]

    Ireland +353 1 637 2141

    U.S. +1 215 867 4948

    Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2024-financial-results-and-provides-2025-financial-guidance-302385001.html

    SOURCE Jazz Pharmaceuticals plc

    Get the next $JAZZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JAZZ

    DatePrice TargetRatingAnalyst
    3/7/2025$145.00 → $179.00Neutral → Buy
    UBS
    2/26/2025Overweight → Neutral
    Cantor Fitzgerald
    2/13/2025$130.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    12/12/2024$140.00 → $175.00Equal-Weight → Overweight
    Morgan Stanley
    6/5/2024$169.00Buy
    Goldman
    1/3/2024$160.00Outperform
    Robert W. Baird
    11/27/2023$170.00 → $135.00Buy → Neutral
    UBS
    9/29/2023Mkt Perform
    Raymond James
    More analyst ratings

    $JAZZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference

      DUBLIN, April 30, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company management will participate in a fireside chat on Wednesday, May 14, 2025, at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST. An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be archived on the website for 30 days. About Jazz PharmaceuticalsJazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharma company whose purpose is to innovate to transfor

      4/30/25 4:15:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

      DUBLIN, April 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the conditional marketing authorization of zanidatamab, an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+)† biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy.1 "This positive CHMP opinion is a welcome step for physicians and patients in Europe who f

      4/25/25 11:27:00 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

      Statistically significant and clinically meaningful progression-free survival (PFS) and overall survival (OS) data for Zepzelca® (lurbinectedin) and atezolizumab (Tecentriq®) combination underscore potential of first-line maintenance therapy for extensive-stage small cell lung cancer, a much-needed advancement for patients Long-term outcomes and survival data for Ziihera® (zanidatamab-hrii) highlight its potential to reshape the treatment paradigm for newly diagnosed HER2+ gastroesophageal cancer patients Efficacy and safety of dordaviprone (ONC201) in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients Jazz to host investor webcast on Tuesday

      4/23/25 4:15:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    Financials

    Live finance-specific insights

    See more
    • Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

      DUBLIN, April 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2025 first quarter financial results and provide a business and financial update.   Audio webcast/conference call:U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926Additional global dial-in numbers are available here.Passcode: 5080203 Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at

      4/22/25 4:15:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Completes Acquisition of Chimerix

      - Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN, April 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc. ("Chimerix") for approximately $935 million in cash. Chimerix is now a wholly owned subsidiary of Jazz. "Bringing Chimerix into Jazz adds a novel medicine to our oncology portfolio and advances our efforts to address unmet patient needs," said Bruce Cozadd, chairman and chief executive officer of Jazz. "Dordaviprone has the potential to become the first an

      4/21/25 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

      – Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 –– Xywav® and Epidiolex® revenues grew 16% and 15% year-over-year, respectively, in 2024 –– Oncology revenues grew 9% year-over-year in 2024, surpassed $1.1 billion –– Ziihera® approved in 2L HER2+ (IHC3+) BTC; first sales achieved in December 2024 –– 2025 guidance reflects continued top- and bottom-line growth – DUBLIN, Feb. 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the full year and fourth quarter of 2024 and provided guidance for 2025. "2024 was another strong year as our proven team delivered significant top- and bottom-line growth along with record total r

      2/25/25 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • August 12, 2021 - FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment

      For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl

      8/12/21 4:25:43 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jazz Pharma upgraded by UBS with a new price target

      UBS upgraded Jazz Pharma from Neutral to Buy and set a new price target of $179.00 from $145.00 previously

      3/7/25 8:10:15 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharma downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Jazz Pharma from Overweight to Neutral

      2/26/25 1:51:25 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharma upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Jazz Pharma from Equal Weight to Overweight and set a new price target of $170.00 from $130.00 previously

      2/13/25 8:08:59 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    SEC Filings

    See more
    • SEC Form 10-Q filed by Jazz Pharmaceuticals plc

      10-Q - Jazz Pharmaceuticals plc (0001232524) (Filer)

      5/7/25 7:33:48 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)

      5/6/25 4:08:30 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Jazz Pharmaceuticals plc

      144 - Jazz Pharmaceuticals plc (0001232524) (Subject)

      5/1/25 4:09:24 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    Leadership Updates

    Live Leadership Updates

    See more

    $JAZZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $JAZZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Jazz Pharmaceuticals Announces CEO Succession Plan

      Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board Mr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total Revenue Board Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025 DUBLIN, Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive Officer (CEO), has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of the Company's next leader, expected by the end of 2025. The Board wil

      12/16/24 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting

      Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN, July 25, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the election of a new independent director, Laura Hamill, to its Board of Directors. Ms. Hamill, a 35-year veteran of the pharmaceutical industry brings broad executive leadership and global commercial operations expertise to the company's Board. Ms. Hamill's election follows the appointment of Patrick Kennedy earlier this year and reflects Jazz's continued focus on Board renewal. At the Annual General meeting held today, shareholders not only elected Ms. Hamill and Mr. Kennedy but also re-

      7/25/24 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer

      NodThera INC ("NodThera" or the "Company") NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership experience, including as President and COO of Jazz Pharmaceuticals and CEO of Sunesis PharmaceuticalsInterim CEO Alan Watt becomes President and CSO including leadership of R&D to further build out NodThera's pioneering work in CNS modulation of chronic inflammatory diseases BOSTON, MA, May 28, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the a

      5/28/24 7:00:00 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson Philip L was granted 15,932 units of Ordinary Shares and bought $1,435,800 worth of Ordinary Shares (12,000 units at $119.65) (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      3/5/24 7:28:40 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

      SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

      2/13/24 5:07:58 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

      SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

      9/11/23 1:33:44 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

      SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

      2/9/23 11:25:15 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman & CEO Cozadd Bruce C sold $176,350 worth of Ordinary Shares (1,500 units at $117.57), decreasing direct ownership by 0.34% to 438,807 units (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      5/5/25 7:00:39 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman & CEO Cozadd Bruce C sold $185,625 worth of Ordinary Shares (1,500 units at $123.75), decreasing direct ownership by 0.34% to 440,307 units (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      4/3/25 5:32:10 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Global Head of R&D & CMO Iannone Robert sold $332,605 worth of Ordinary Shares (2,403 units at $138.41), decreasing direct ownership by 3% to 79,621 units (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      3/12/25 2:24:35 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care